Hans Tanner
Director/Board Member at PAION AG
Net worth: 76 153 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ingmar Hoerr | M | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 21 years |
| Friedrich von Bohlen und Halbach | M | 60 |
Cosmo Holding SpA
 Cosmo Holding SpA Pharmaceuticals: MajorHealth Technology Cosmo Holding SpA manufactures and markets pharmaceutical products. It develops technologies in the sector of modified drug release with oral, topical, and transmucosal applications. The company was founded in 1996 and is headquartered in Milan, Italy.
Cosmo Pharmaceuticals SA
 Cosmo Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cosmo Pharmaceuticals SA operates as a pharmaceutical company that engages in the manufacturing of pharmaceutical drugs. It focuses on the development of gastro-intestinal pharmaceutical products for the treatment of inflammatory bowel diseases, colon infections and colon diagnosis, and treated skin disorders. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Lainate, Italy.
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 19 years |
| Markus Baumann | M | 61 | 26 years | |
| Pierpaolo Guzzo | M | 56 | 9 years | |
| Alessandro Della Chà | M | 61 |
Cosmo Pharmaceuticals SA
Cosmo Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cosmo Pharmaceuticals SA operates as a pharmaceutical company that engages in the manufacturing of pharmaceutical drugs. It focuses on the development of gastro-intestinal pharmaceutical products for the treatment of inflammatory bowel diseases, colon infections and colon diagnosis, and treated skin disorders. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Lainate, Italy. | 18 years |
| Maria Grazia Roncarolo | M | 69 |
Cosmo Pharmaceuticals SA
Cosmo Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cosmo Pharmaceuticals SA operates as a pharmaceutical company that engages in the manufacturing of pharmaceutical drugs. It focuses on the development of gastro-intestinal pharmaceutical products for the treatment of inflammatory bowel diseases, colon infections and colon diagnosis, and treated skin disorders. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Lainate, Italy. | 12 years |
| Florian von der Muelbe | M | 52 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 24 years |
| Marco Pasero | M | 58 | 9 years | |
| Arik Zucker | M | - |
Qvanteq AG
 Qvanteq AG BiotechnologyHealth Technology Qvanteq AG develops novel bioactive stents to address and overcome the clinical adverse. Its products include technology, intracranial stents, Qstent Periphry, and Qstent Coronary. The company was founded in 2009 and is headquartered in Zurich, Switzerland. | 15 years |
| Laurent Sigismondi | M | 48 | 9 years | |
| Gregor Siebert | M | - | 2 years | |
| Luigi Moro | M | 73 | 25 years | |
| Alessandro Mazzetti | M | 72 |
Cosmo Pharmaceuticals SA
Cosmo Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cosmo Pharmaceuticals SA operates as a pharmaceutical company that engages in the manufacturing of pharmaceutical drugs. It focuses on the development of gastro-intestinal pharmaceutical products for the treatment of inflammatory bowel diseases, colon infections and colon diagnosis, and treated skin disorders. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Lainate, Italy. | 7 years |
| Dieter A. Enkelmann | M | 64 |
Cosmo Pharmaceuticals SA
Cosmo Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cosmo Pharmaceuticals SA operates as a pharmaceutical company that engages in the manufacturing of pharmaceutical drugs. It focuses on the development of gastro-intestinal pharmaceutical products for the treatment of inflammatory bowel diseases, colon infections and colon diagnosis, and treated skin disorders. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Lainate, Italy. | 18 years |
| Andreas Willy Keller | M | 79 | 22 years | |
| René Stenger | M | - |
Lifematrix Technologies AG
 Lifematrix Technologies AG Miscellaneous Commercial ServicesCommercial Services Lifematrix Technologies AG develops human cell-derived and off-the-shelf available tissue-engineered implants. The company is based in Zurich, Switzerland. The Swiss company was founded by René Stenger and Robin Müller. The CEO is Maximilian Emmert. | - |
| Michael Brosnan | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 1 years |
| Baron Jean Stéphenne | M | 73 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
| Marco Gadola | M | 61 | 5 years | |
| Adrian Thomas Keller | M | 73 | 22 years | |
| Craig Tooman | M | 58 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 5 years |
| Timothy M. Wright | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 6 years |
| Kevin Joseph Donovan | M | 65 | 8 years | |
| Niall Donnelly | M | 52 | 8 years | |
| Robin Müller | M | - |
Lifematrix Technologies AG
Lifematrix Technologies AG Miscellaneous Commercial ServicesCommercial Services Lifematrix Technologies AG develops human cell-derived and off-the-shelf available tissue-engineered implants. The company is based in Zurich, Switzerland. The Swiss company was founded by René Stenger and Robin Müller. The CEO is Maximilian Emmert. | - |
| Stefan Butz | M | 56 | 7 years | |
| Ido Wallach | M | 49 | 5 years | |
| Eunice Zehnder-Lai | F | 57 | 6 years | |
| Debra Stephanie Barker | M | 61 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 2 years |
| Maximilian Emmert | M | - |
Lifematrix Technologies AG
Lifematrix Technologies AG Miscellaneous Commercial ServicesCommercial Services Lifematrix Technologies AG develops human cell-derived and off-the-shelf available tissue-engineered implants. The company is based in Zurich, Switzerland. The Swiss company was founded by René Stenger and Robin Müller. The CEO is Maximilian Emmert. | - |
| Igor Splawski | M | 56 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 4 years |
| Bernd Winterhalter | M | 65 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 5 years |
| Mariola Fotin-Mleczek | M | 50 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 18 years |
| Ralf Clemens | M | 71 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
| Michael Schlenk | M | - | 2 years | |
| Mathias Hothum | M | 58 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
| Pierre Kemula | M | 50 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 8 years |
| Armin W. Mäder | M | - |
Qvanteq AG
Qvanteq AG BiotechnologyHealth Technology Qvanteq AG develops novel bioactive stents to address and overcome the clinical adverse. Its products include technology, intracranial stents, Qstent Periphry, and Qstent Coronary. The company was founded in 2009 and is headquartered in Zurich, Switzerland. | 15 years |
| Ralf Penner | M | - | 15 years | |
| Jack Clemons | M | 58 | 5 years | |
| Till Leisner | M | 42 | - | |
| Annette Koehler | M | 57 | 6 years | |
| Martin Eberhard | M | 66 | 14 years | |
| Wolfgang Baier | M | 50 | 5 years | |
| Petra Salesny | M | 53 | 6 years | |
| Hans Baumgartner | M | 70 | 18 years | |
| Antoine Mangin | M | 48 | 4 years | |
| Malte Greune | M | 59 | 3 years | |
| Dave Wood | M | - | 5 years | |
| Antony Blanc | M | 57 | 4 years | |
| Viola Bronsema | M | 61 | 4 years | |
| Klaus Schollmeier | M | 67 | 2 years | |
| Chris Tanner | M | - |
Lifematrix Technologies AG
Lifematrix Technologies AG Miscellaneous Commercial ServicesCommercial Services Lifematrix Technologies AG develops human cell-derived and off-the-shelf available tissue-engineered implants. The company is based in Zurich, Switzerland. The Swiss company was founded by René Stenger and Robin Müller. The CEO is Maximilian Emmert. | - |
| Hanno Elbraechter | M | 44 | 10 years | |
| Tilmann Bur | M | 60 | 1 years | |
| Jean Stephenne | M | 75 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
| Sebastian Werner | M | - | 2 years | |
| Davide Malavasi | M | 51 | 13 years | |
| Bijay Singh | M | 60 | 9 years | |
| Karin Louise Dorrepaal | M | 63 | 12 years | |
| Fidelis M. Götz | M | 58 | 6 years | |
| Stephen John Ferraby | M | 60 | 9 years | |
| Suk-Woo Ha | M | - |
Qvanteq AG
Qvanteq AG BiotechnologyHealth Technology Qvanteq AG develops novel bioactive stents to address and overcome the clinical adverse. Its products include technology, intracranial stents, Qstent Periphry, and Qstent Coronary. The company was founded in 2009 and is headquartered in Zurich, Switzerland. | - |
| Gabriel Baertschi | M | 50 | 1 years | |
| Markus Guilherme Dieken | M | - | 5 years | |
| Alexander Zehnder | M | 54 | 1 years | |
| Sam Oh | M | 58 | 3 years | |
| Ulrike Gnad-Vogt | M | - |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 13 years |
| Myriam Mendila | M | 58 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Diana Harbort | F | 57 | 7 years | |
| Jörg Wolfgang Wolle | M | 67 | 19 years | |
| Robert Mills | M | 74 | 10 years | |
| Oliver M. Bartholet | M | 58 | 20 years | |
| Jan Egbert de Vries | M | 80 | - | |
| Michele Trogni | F | 59 | 17 years | |
| David Hale | M | 75 | 2 years | |
| Eimar Cowhey | F | 58 | - | |
| Øyvind Bjordal | M | 58 | - | |
| Bernhard Schürmann | M | 76 | 7 years | |
| Richard Jones | M | 55 |
Cosmo Pharmaceuticals SA
Cosmo Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cosmo Pharmaceuticals SA operates as a pharmaceutical company that engages in the manufacturing of pharmaceutical drugs. It focuses on the development of gastro-intestinal pharmaceutical products for the treatment of inflammatory bowel diseases, colon infections and colon diagnosis, and treated skin disorders. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Lainate, Italy. | - |
| André Lagger | M | 62 | - | |
| Paul H. Arni | M | 60 | 15 years | |
| Heinrich Andreas Baumann | M | 72 | 23 years | |
| Gianluigi Bertolli | M | 72 |
Cosmo Holding SpA
Cosmo Holding SpA Pharmaceuticals: MajorHealth Technology Cosmo Holding SpA manufactures and markets pharmaceutical products. It develops technologies in the sector of modified drug release with oral, topical, and transmucosal applications. The company was founded in 1996 and is headquartered in Milan, Italy.
Cosmo Pharmaceuticals SA
Cosmo Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cosmo Pharmaceuticals SA operates as a pharmaceutical company that engages in the manufacturing of pharmaceutical drugs. It focuses on the development of gastro-intestinal pharmaceutical products for the treatment of inflammatory bowel diseases, colon infections and colon diagnosis, and treated skin disorders. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Lainate, Italy. | 2 years |
| Wolfgang Söhngen | M | - | 19 years | |
| Gilbert Achermann | M | 60 | 10 years | |
| John Jenkins | M | 66 | 12 years | |
| Gonpo Tsering | M | 68 | 13 years | |
| Rolf A. Meyer | M | 80 | 10 years | |
| Patrick Schildknecht | M | 52 | 1 years | |
| Rainer-Marc Frey | M | 61 | 10 years | |
| Robert Peugeot | M | 74 | 11 years | |
| Rolf Stahel | M | 79 |
Cosmo Holding SpA
Cosmo Holding SpA Pharmaceuticals: MajorHealth Technology Cosmo Holding SpA manufactures and markets pharmaceutical products. It develops technologies in the sector of modified drug release with oral, topical, and transmucosal applications. The company was founded in 1996 and is headquartered in Milan, Italy.
Cosmo Pharmaceuticals SA
Cosmo Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cosmo Pharmaceuticals SA operates as a pharmaceutical company that engages in the manufacturing of pharmaceutical drugs. It focuses on the development of gastro-intestinal pharmaceutical products for the treatment of inflammatory bowel diseases, colon infections and colon diagnosis, and treated skin disorders. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Lainate, Italy. | 2 years |
| Roberto Camerini | M | 61 | 2 years | |
| Maurizio Baldassarini | M | - | 4 years | |
| Eileen S. Fusco | F | 67 | 3 years | |
| Nazir Badat | M | - | - | |
| Hervé de Kergrohen | M | 66 | 1 years | |
| Daniel Rüegger | M | 63 | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 48 | 48.48% |
| Germany | 30 | 30.30% |
| Italy | 17 | 17.17% |
| Ireland | 12 | 12.12% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Hans Tanner
- Personal Network
